HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text (PDF) Correspondence: Submit a response Alert me when this article is cited Alert me when Correspondence are posted Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Brew, B. J. Articles by Price, R. W. Search for Related Content PubMed PubMed Citation Articles by Brew, B. J. Articles by Price, R. W.

Cerebrospinal fluid ß₂ microglobulin in patients infected with human immunodeficiency virus

Department of Neurology, Memorial Sloan Kettering Cancer Center, New York, NY (Drs. Brew, Paul, and Price, and Ms. Khan)
Department of Clinical Chemistry, Memorial Sloan Kettering Cancer Center, New York, NY (Drs. Bhalla, Fleisher, and Schwartz).

We prospectively evaluated CSF concentrations of ß₂ microglobulin (ß₂M) in 65 human immunodeficiency virus type 1 seropositive patients. The highest concentrations occurred in those with lymphoma, neurologic opportunistic infections, and acquired immune deficiency syndrome dementia complex (ADC). There was a high correlation between the CSF ß₂M concentration and ADC severity, suggesting that CSF ß₂M may be useful as a marker for the development, progression, and perhaps response to treatment of ADC. Elevated CSF ß₂M was not due to CSF pleocytosis and was usually independent of blood-brain barrier dysfunction.

Address correspondence and reprint requests to Dr. Price, Department of Neurology, Medical School, Box 295 UMHC, 420 Delaware Street SE, Minneapolis, MN 55455-0323.

Supported by US Public Health Service research grant NS-25701 and a grant from the Rudin Foundation.

Received November 2, 1988. Accepted for publication in final form December 12, 1988.

This article has been cited by other articles:

				D. B. Clifford, J. C. McArthur, G. Schifitto, K. Kieburtz, M. P. McDermott, S. Letendre, B. A. Cohen, K. Marder, R. J. Ellis, and C. M. Marra A randomized clinical trial of CPI-1189 for HIV-associated cognitive-motor impairment Neurology, November 26, 2002; 59(10): 1568 - 1573. [Abstract] [Full Text] [PDF]

				B. A. Navia, U. Dafni, D. Simpson, T. Tucker, E. Singer, J. C. McArthur, C. Yiannoutsos, L. Zaborski, S. A. Lipton, and the AIDS Clinical Trial Group* A phase I/II trial of nimodipine for HIV-related neurologic complications Neurology, July 1, 1998; 51(1): 221 - 228. [Abstract] [Full Text] [PDF]

				K. D. Kieburtz, L. G. Epstein, H. A. Gelbard, and J. T. Greenamyre Excitotoxicity and Dopaminergic Dysfunction in the Acquired Immunodeficiency Syndrome Dementia Complex: Therapeutic Implications Arch Neurol, December 1, 1991; 48(12): 1281 - 1284. [Abstract] [PDF]